FilingReader Intelligence
Huahai Pharmaceutical's subsidiary gains approval for clinical trials
May 24, 2025 at 05:10 AM UTC•By FilingReader AI
Zhejiang Huahai Pharmaceutical Co., Ltd. (SSE:600521) announced that its subsidiary, Shanghai Huahai Pharma, has received approval from New Zealand's MEDSAFE and the Health and Disability Ethics Committees (HDEC) to conduct Phase I clinical trials for its drug, HB0043.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime